Taiwan's TLC Granted Orphan Status in US for Lymphoma Drug

TLC, a Taiwan novel drug maker, was granted Orphan Drug designation in the US for TLC178, an oral drug that targets cutaneous T-cell lymphoma. Lymphoma is one of the most common forms of blood cancer, and cutaneous T-cell lymphoma is a common T-cell lymphoma. Two weeks ago, TLC was approved to begin US trials of TLC178. TLC178, a lipid-encapsulated form of vinorelbine, is a targeted form of the chemotherapy that is designed to increase efficacy and lower toxicity. More details.... Stock Symbol: (TT: 4152) Share this with colleagues: // //